Abstract: This invention relates to nitroproline derivative compounds and procedures for their preparation and the preparation of pharmaceutical compositions containing the compounds. The invention also relates to the administration of compounds of the invention as agents for the treatment of mammalian diseases whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable cellular and molecular activities or responses induced by integrin-dependent molecular interactions.
Type:
Grant
Filed:
April 14, 2006
Date of Patent:
November 4, 2008
Assignees:
Universidad del Pais Vasco, Dominion Pharmakine S.L.
Inventors:
Fernando Pedro Cossio, Eneko Aldaba Arévalo, Yosu Ion Vara Salazr, Aizpea Zubia Olascoaga, Silvia Vivanco Amato, Miren Lorea Mendoza Arteche, María Valcárcel Cuesta, Fernando Vidal Vanaclocha
Abstract: The invention relates to the treatment of disorders or diseases mediated by LFA-1/ICAM-1 molecular interaction. This is based on the use of novel chemical compounds capable of inhibiting said interaction, and more particularly, to pharmaceutical compositions containing these compounds.
Type:
Application
Filed:
November 14, 2005
Publication date:
October 9, 2008
Applicants:
DOMINION PHARMAKINE S.L., UNIVERSIDAD DEL PAIS VASCO
Inventors:
Fernando Pedro Cossio Mora, Eider San Sebastian Larzabal, Miren Lorea Mendoza Arteche, Aizpea Zubia Olascoaga, Maria Valcarcel Cuesta, Yosu Ion Vara Salazar, Miren Sorne Solaun Aguirre, Jose Javier Lopez Pestana, Natalia Gallot Escobal, Fernando Vidal Vanaclocha
Abstract: The invention describes an in vitro method for detecting a psychiatric disorder occurring with psychosis selected from schizophrenia and bipolar disorder in an individual who has suffered a first psychotic episode, or for determining the state or severity of said disorder, or for monitoring the effect of a therapy administered to an individual who suffers said disorder, or for evaluating the predisposition of an individual presenting a prodromal symptom to develop said disorder, based on the use of the brain-derived neutrophic factor (BDNF) as a marker.
Type:
Application
Filed:
July 10, 2007
Publication date:
April 3, 2008
Applicants:
UNIVERSIDAD DEL PAIS VASCO, HOSPITAL SANTIAGO APOSTOL
Inventors:
Carlos Almau, Aitor Fernandez de Larrea, Ana Pinto
Abstract: Newly-isolated and purified metabolites which are effective in regulating the development of at least one filamentous fungal microorganism species are disclosed. These compounds, which are referred to as conidiogenol and conidiogenone, may be used to induce conidiation in and/or to inhibit the growth of populations of such fungal species. The compounds are preferably produced by culture of the fungal species Penicillium cyclopium, and may be subsequently recovered from the culture medium and purified. Methods of using and methods of producing these compounds are also disclosed.
Type:
Grant
Filed:
October 31, 2001
Date of Patent:
January 27, 2004
Assignee:
Universidad del Pais Vasco/Euskal Herriko
Unibersitatea
Inventors:
Unai Ugalde, Tomas Roncal, Olov Sterner